Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREAT ambroxol trial in GBA1-mutation Parkinson's disease
NL-OMON60924Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ambroxol in Parkinson's disease (PD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: MDS-UPDRS Part III motor score at 60 weeks. Started Sep 2024; status: recruiting.
02
Drugs
ambroxol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60924.